Currently, the National Comprehensive Cancer Network clinical practice guidelines [9] recommend KRAS-mutant CRC patients with metastatic or advanced disease to be treated with chemotherapy regimens including oxaliplatin, leucovorin, 5-fluorouracil, bevacizumab, capecitabine, and irinotecan. Here, KRAS is linked to colorectal carcinoma.